Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia

NCT06718686 is registered in ClinicalTrials.gov with Jasmohan Bajaj as lead sponsor.

NCT NCT06718686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06718686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin in Dementia Trial (RIDE): Gut-Brain Modulation With Rifaximin SSD in Dementia
Lead sponsor
Jasmohan Bajaj
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 30, 2024
Completion date
December 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dementia alzheimer type, dementia associated with cerebrovascular disease